There is a flurry of news surrounding Edwards Lifesciences Corp EW highlighting crucial operational updates, stock movement, and financial outlook. Edwards Lifesciences is set to reveal Q2 2025 results, with structural heart innovations feeding its growth.
Despite analyst concern over current growth prospects, the corporation maintains an optimistic outlook with Edwards' MiCLASP and PASCAL system trials showing promise in heart valve repair. Amidst class action lawsuits for securities fraud, investors are urged to protect their rights. Nevertheless, the company depicted strong Q1 2025 earnings and an upward adjustment of sales view for 2025.
Morgan Stanley has revised the company's price target to $81 from $75. However, class actions against securities fraud and global layoffs bring a mixed vibe. Despite these challenges, Edwards Lifesciences continues to innovate, reflected in its SAPIEN M3 and TAVR receiving CE mark and FDA approval, respectively.
The corporation recently sold its Critical Care product group to BD for $4.2 billion and plans to acquire JenaValve and Endotronix, expanding its structural heart portfolio.
Edwards Lifesciences Corp EW News Analytics from Thu, 26 Oct 2023 07:00:00 GMT to Sat, 19 Jul 2025 12:15:38 GMT - Rating 2 - Innovation 6 - Information 8 - Rumor 4
